Nanogen Reports Results of First Quarter Placements of Its NanoChip(TM) Molecular Biology Workstation

Apr 03, 2001, 01:00 ET from Nanogen, Inc.

    SAN DIEGO, April 3 /PRNewswire/ -- Nanogen, Inc. (Nasdaq:   NGEN) announced
 today that during the first quarter of 2001, it placed three additional
 NanoChip(TM) Molecular Biology Workstations.  The placements included one
 title transfer transaction representing a sale and recorded as product
 revenue, and two non-title transfer transactions.  The two non-title transfer
 transactions consisted of a shipment to a new customer pursuant to a
 Development Site Agreement and a second shipment to a current customer
 resulting from the expansion of an existing Development Site Agreement.
     Also during the first quarter of 2001, Nanogen began a collaborative
 relationship with American Medical Laboratories (AML) in which AML is
 performing comparative analyses of the NanoChip(TM) Molecular Biology
 Workstation against the products of various other companies.  The results of
 this collaboration may eventually lead to the development of molecular
 diagnostic test protocols to be performed on the NanoChip(TM) Molecular
 Biology Workstation.  In addition, Nanogen substantially completed the hiring
 of its domestic and international sales and marketing teams and continued to
 train its newly hired personnel.
     "We are pleased to have continued our progress on the commercial and
 technology fronts during the first quarter, including the commencement of gene
 expression beta testing, progress in the development of electronic technology
 for high throughput screening of protein kinases and the further expansion of
 our patent portfolio," commented Howard C. Birndorf, Nanogen's Chairman and
 Chief Executive Officer.  "As noted in our most recent conference call, we
 believe that, once our sales and marketing teams are fully trained, the
 placement of NanoChip(TM) Molecular Biology Workstations should ramp up over
 the coming months and towards the end of the year," Mr. Birndorf continued.
     Nanogen markets its NanoChip(TM) Molecular Biology Workstation system to
 scientists and genomics laboratories, setting new standards for SNP scoring.
 In addition, Nanogen is developing a series of electronics-based products to
 help researchers and clinical healthcare providers accelerate their practical
 understanding and use of genomic information.  The products introduced and
 under development are intended to provide quick and accurate analysis of DNA,
 RNA and proteins, and may eventually "bridge" the gap between the research and
 clinical settings.  The Nanogen system is intended for research use only and
 not for use in diagnostic procedures.  For additional information please visit
 Nanogen's web site at www.nanogen.com.
 
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including whether the
 Company's NanoChip(TM) system can be successfully commercialized, whether
 products under development can be successfully developed and commercialized,
 whether results reported by our customers or partners can be identically
 replicated, whether the Company's collaborations will continue to be funded,
 and other risks and uncertainties discussed under the caption "Factors That
 May Affect Results" and elsewhere in the Company's Form 10-K for the year
 ended December 31, 2000  filed with the Securities and Exchange Commission.
 These forward-looking statements speak only as of the date hereof.  The
 Company disclaims any intent or obligation to update these forward-looking
 statements.
 
 

SOURCE Nanogen, Inc.
    SAN DIEGO, April 3 /PRNewswire/ -- Nanogen, Inc. (Nasdaq:   NGEN) announced
 today that during the first quarter of 2001, it placed three additional
 NanoChip(TM) Molecular Biology Workstations.  The placements included one
 title transfer transaction representing a sale and recorded as product
 revenue, and two non-title transfer transactions.  The two non-title transfer
 transactions consisted of a shipment to a new customer pursuant to a
 Development Site Agreement and a second shipment to a current customer
 resulting from the expansion of an existing Development Site Agreement.
     Also during the first quarter of 2001, Nanogen began a collaborative
 relationship with American Medical Laboratories (AML) in which AML is
 performing comparative analyses of the NanoChip(TM) Molecular Biology
 Workstation against the products of various other companies.  The results of
 this collaboration may eventually lead to the development of molecular
 diagnostic test protocols to be performed on the NanoChip(TM) Molecular
 Biology Workstation.  In addition, Nanogen substantially completed the hiring
 of its domestic and international sales and marketing teams and continued to
 train its newly hired personnel.
     "We are pleased to have continued our progress on the commercial and
 technology fronts during the first quarter, including the commencement of gene
 expression beta testing, progress in the development of electronic technology
 for high throughput screening of protein kinases and the further expansion of
 our patent portfolio," commented Howard C. Birndorf, Nanogen's Chairman and
 Chief Executive Officer.  "As noted in our most recent conference call, we
 believe that, once our sales and marketing teams are fully trained, the
 placement of NanoChip(TM) Molecular Biology Workstations should ramp up over
 the coming months and towards the end of the year," Mr. Birndorf continued.
     Nanogen markets its NanoChip(TM) Molecular Biology Workstation system to
 scientists and genomics laboratories, setting new standards for SNP scoring.
 In addition, Nanogen is developing a series of electronics-based products to
 help researchers and clinical healthcare providers accelerate their practical
 understanding and use of genomic information.  The products introduced and
 under development are intended to provide quick and accurate analysis of DNA,
 RNA and proteins, and may eventually "bridge" the gap between the research and
 clinical settings.  The Nanogen system is intended for research use only and
 not for use in diagnostic procedures.  For additional information please visit
 Nanogen's web site at www.nanogen.com.
 
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including whether the
 Company's NanoChip(TM) system can be successfully commercialized, whether
 products under development can be successfully developed and commercialized,
 whether results reported by our customers or partners can be identically
 replicated, whether the Company's collaborations will continue to be funded,
 and other risks and uncertainties discussed under the caption "Factors That
 May Affect Results" and elsewhere in the Company's Form 10-K for the year
 ended December 31, 2000  filed with the Securities and Exchange Commission.
 These forward-looking statements speak only as of the date hereof.  The
 Company disclaims any intent or obligation to update these forward-looking
 statements.
 
 SOURCE  Nanogen, Inc.